Novartis AG (SWX:NOVN)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 200.90B |
| Revenue (ttm) | 44.95B |
| Net Income (ttm) | 11.48B |
| Shares Out | 1.92B |
| EPS (ttm) | 5.82 |
| PE Ratio | 17.99 |
| Forward PE | 14.88 |
| Dividend | 3.50 (3.36%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 2,888,118 |
| Average Volume | 2,608,147 |
| Open | 104.08 |
| Previous Close | 104.08 |
| Day's Range | 103.90 - 105.04 |
| 52-Week Range | 81.10 - 106.88 |
| Beta | 0.44 |
| RSI | 62.85 |
| Earnings Date | Oct 28, 2025 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial numbers in USD Financial StatementsNews
New, effective anti-malaria drug could help fight rising resistance, says Novartis
A new antimalarial drug developed by Novartis is as effective as existing treatments and could help tackle rising drug resistance, the company said on Wednesday as it presented final-stage trial resul...
Novartis AG Basel Reaches Analyst Target Price
In recent trading, shares of Novartis AG Basel (Symbol: NVS) have crossed above the average analyst 12-month target price of $127.00, changing hands for $127.11/share. When a stock reaches the target ...
Novartis launches new manufacturing facility in California
Novartis (NVS) Unveils New Radioligand Facility in California
Novartis (NVS) Unveils New Radioligand Facility in California
Novartis opens new plant in California to make cancer drugs
Swiss drugmaker Novartis said on Monday it has opened a new 10,000-square-foot factory in Carlsbad, California, to make cancer treatments, as part of its pledge to invest billions into building U.S. s...
Metsera gets higher bids from Novartis, Pfizer in bidding war
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline
Basel, November 4, 2025 – Novartis will present new data from 33 abstracts across its Cardiovascular, Renal, and Metabolic (CRM) disease portfolio at the upcoming American Society of Nephrology (ASN) ...
Meharry and Novartis Partner on HEART Initiative for Healthier Communities
NASHVILLE, Tenn.--(BUSINESS WIRE)--The School of Global Health at Meharry Medical College, in partnership with Novartis, today announced the launch of Health Assessments and Rapid Transformation (HEAR...
Key deals this week: Qorvo, Chewy, Sotherly Hotels, Novartis, CSG Systems, and more
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
Novartis is set to boost its developmental pipeline with this acquisition.
NATCO Pharma launches Generic Everolimus Tablets 1mg in the U.S. market
NATCO Pharma Limited has announced the launch of Everolimus Tablets 1mg, a generic version of Zortress® by Novartis, under the...
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies Transcript
Novartis AG ( NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies October 30, 2025 11:30 AM EDT Company Participants Isabella Zinck Shreeram Aradhye - President of Develop...
Novartis AG (NVS) Q3 2025 Earnings Call Highlights: Robust Growth in Key Brands and Strategic ...
Novartis AG (NVS) Q3 2025 Earnings Call Highlights: Robust Growth in Key Brands and Strategic Initiatives
Novartis AG (NVS) Discusses Immunology Portfolio Update and Advances in Autoimmune Therapies - Slideshow
Novartis (NVS) Reveals Promising Ianalumab Data for Sjogren's Disease
Novartis (NVS) Reveals Promising Ianalumab Data for Sjogren's Disease
Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren's disease Phase III trials
Basel, October 29, 2025 – Novartis today presented new ianalumab data in Sjögren's disease, the second most prevalent rheumatic autoimmune disease2, at a late-breaker presentation during the American ...
Is the Market Bullish or Bearish on Novartis AG?
Novartis AG's (NYSE: NVS) short interest as a percent of float has fallen 4.35% since its last report. According to exchange reported data, there are now 4.35 million shares sold short , which is 0.2...
3 Investable Laggards In An Overbought Market
The market continues to trade deeper in overbought territory based on most traditional valuation metrics. Most of the gains over the past three years have been driven by tech giants riding the AI Revo...
European Stocks Dip Amid Disappointing Novartis and BNP Paribas Results
European Stocks Dip Amid Disappointing Novartis and BNP Paribas Results
Swiss Market Ends Notably Lower; Sika, Novartis Decline Sharply
(RTTNews) - The Switzerland market kept drifting lower and lower after a weak start on Tuesday and eventually ended the day's session firmly in negative territory.
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Novartis AG (NYSE:NVS) Q3 2025 Earnings Call October 28, 2025 9:00 AM EDT Company Participants Sloan Simpson - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirs...
Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition
Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.
Novartis Profit Rises on Cancer Drug Momentum(edit)
Novartis Profit Rises on Cancer Drug Momentum(edit)
Novartis completes acquisition of Tourmaline Bio
Basel, October 28, 2025 - Novartis today announced that it has successfully completed its acquisition of Tourmaline Bio, Inc. (“Tourmaline”). With the completion of the acquisition, shares of common s...
Novartis AG 2025 Q3 - Results - Earnings Call Presentation
2025-10-28. The following slide deck was published by Novartis AG in conjunction with their 2025 Q3 earnings call.